Endocyte Inc. has announced the initiation of a randomized Phase II clinical study of the company's investigational drug EC145 in women with platinum-resistant ovarian cancer. The phase II trial, also called the "PRECEDENT study," will evaluate the efficacy and safety of EC145 when administered in combination with pegylated liposomal doxorubicin (PLD). PLD is widely used as a standard therapy for women with platinum-resistant ovarian cancer. Read more ...
Friday, February 20, 2009
Nanoscopic Changes To Pancreatic Cells Reveal Cancer
Nanoscopic Changes To Pancreatic Cells Reveal Cancer
A team of researchers in Chicago has developed a way to examine cell biopsies and detect never-before-seen signs of early-stage pancreatic cancer.
A team of researchers in Chicago has developed a way to examine cell biopsies and detect never-before-seen signs of early-stage pancreatic cancer, according to a new paper in the Optical Society (OSA) journal Optics Letters. Though the new technique has not yet proven effective in double-blind clinical trials, it may one day help diagnose cancers of the pancreas and, potentially, other organs at their earliest and most treatable stages, before they spread.
Source:
Optical Society of America
Subscribe to:
Posts (Atom)
